New Delhi The corona virus is good news for infected patients. The leading biotechnology company, Biocon, said on Monday that it would introduce the biologic drug itolizumab for the treatment of moderate to severe COVID-19 patients, which would cost around 8,000 per vial. The company has stated that it is marketing etolizumab injection (25 mg / five ml) for emergency use in India for the treatment of cytokine release syndrome in the case of moderate to severe acute respiratory distress syndrome (ARDS) due to Kovid-19. Has been approved by the Controller General of Indian Medicine (DCGI).
Biocon had earlier stated in a regulatory notice that itolizumab is the first novel biological treatment approved anywhere in the world, treating patients suffering from severe complications of Kovid-19.
Kiran Mazdar-Shaw, acting president of Biocon, said that until the vaccine comes, we need life-saving medicines. I think what we are doing around the world is that we can reuse drugs or develop new drugs to treat this epidemic.
He said that even if we get a vaccine by the end of this year or early next year, there is no guarantee that there will be no re-infection, there is no guarantee that the way we can Hoping to work, it will work in the same way. So we need to be prepared.
Over 3 lakh active cases in India
According to the Indian Council of Medical Research, as of July 13, 1,20,92,503 samples of corona virus infected were tested. Of these, 2,86,247 samples were tested on 13 July. According to the Health Ministry, there have been 28,498 new cases of corona virus in India and 553 deaths in the last 24 hours. The total number of positive cases has increased to 9,06,752 with 3,11,565 active cases. There is good news among all that 5,71,460 have been cured. So far 23,727 deaths have occurred in India.
